Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI LODR Regulations’), Shilpa Medicare has informed that the Securities Issue Committee of the Board of Directors of the Company has, at its meeting held today October 06, 2025, accorded approval for the allotment of 9,77,90,908 Equity Shares of ?1/- each as fully paid-up Bonus Equity Shares in the ratio of 1:1 (i.e., one new Bonus Equity Share of ?1 each for every one existing Equity Share of ?1 each) to the shareholders of the Company as on the Record Date, October 03, 2025. The Bonus Equity Shares so allotted shall rank in all respects with the existing fully paid-up equity shares of the Company Consequent to the said allotment, the issued, subscribed and paid-up Equity Share Capital of the Company, as details enclosed. The aforesaid information is also disclosed on the website of the company https://www.vbshilpa.com/.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: